ATE340190T1 - Cytochrome p450 2c9 kristalle, strukturen und dessen verwendung - Google Patents

Cytochrome p450 2c9 kristalle, strukturen und dessen verwendung

Info

Publication number
ATE340190T1
ATE340190T1 AT02770119T AT02770119T ATE340190T1 AT E340190 T1 ATE340190 T1 AT E340190T1 AT 02770119 T AT02770119 T AT 02770119T AT 02770119 T AT02770119 T AT 02770119T AT E340190 T1 ATE340190 T1 AT E340190T1
Authority
AT
Austria
Prior art keywords
structures
cytochrome
crystals
crystallised
ligands
Prior art date
Application number
AT02770119T
Other languages
English (en)
Inventor
Pamela Ann Williams
Jose Marie Cosme
Alison Ward
Suzanne Brewerton
Bruce John Hamilton
Harren Jhoti
Michelle Ann Jones
Laurent M M Vuillard
Mark Gareth Williams
Original Assignee
Astex Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astex Therapeutics Ltd filed Critical Astex Therapeutics Ltd
Application granted granted Critical
Publication of ATE340190T1 publication Critical patent/ATE340190T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0077—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with a reduced iron-sulfur protein as one donor (1.14.15)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/42—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4
    • C07D311/56—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4 without hydrogen atoms in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/80—Cytochromes
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Medical Informatics (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT02770119T 2001-10-25 2002-10-25 Cytochrome p450 2c9 kristalle, strukturen und dessen verwendung ATE340190T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US33058501P 2001-10-25 2001-10-25
US33942101P 2001-12-14 2001-12-14
US34126701P 2001-12-20 2001-12-20
US39658802P 2002-07-18 2002-07-18

Publications (1)

Publication Number Publication Date
ATE340190T1 true ATE340190T1 (de) 2006-10-15

Family

ID=27502422

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02770119T ATE340190T1 (de) 2001-10-25 2002-10-25 Cytochrome p450 2c9 kristalle, strukturen und dessen verwendung

Country Status (6)

Country Link
US (1) US20030170842A1 (de)
EP (1) EP1438337B1 (de)
JP (1) JP2005522989A (de)
AT (1) ATE340190T1 (de)
DE (2) DE60214869T2 (de)
WO (1) WO2003035693A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070179716A1 (en) * 2001-04-02 2007-08-02 Astex Therapeutics Limited Crystal structure of cytochrome P450 3A4 and uses thereof
US20050159901A1 (en) * 2001-04-02 2005-07-21 Astex Technology Limited Crystal structure of cytochrome P450
US7148046B2 (en) * 2001-04-02 2006-12-12 Astex Therapeutics Limited Crystal structure of cytochrome P450
US20050032119A1 (en) * 2001-04-02 2005-02-10 Astex Technology Ltd. Crystal structure of cytochrome P450
US20060116826A1 (en) * 2001-10-25 2006-06-01 Astex Therapeutics Limited Crystals of cytochrome P450 2C9, structures thereof and their use
US20040053383A1 (en) * 2001-10-25 2004-03-18 Astex Technology Ltd. Crystals of cytochrome P450 2C9, structures thereof and their use
DE02735610T1 (de) * 2002-05-30 2005-06-23 Astex Technology Ltd., Cambridge Methoden zur reinigung von cytochrom p450 proteinen und deren kristallisierung
GB2456236B8 (en) 2007-03-22 2009-12-09 Heptares Therapeutics Ltd Stable muscarinic receptor mutants
GB0724051D0 (en) 2007-12-08 2008-01-16 Medical Res Council Mutant proteins and methods for producing them
GB0724860D0 (en) 2007-12-20 2008-01-30 Heptares Therapeutics Ltd Screening
GB0802474D0 (en) 2008-02-11 2008-03-19 Heptares Therapeutics Ltd Mutant proteins and methods for selecting them
GB0910725D0 (en) 2009-06-22 2009-08-05 Heptares Therapeutics Ltd Mutant proteins and methods for producing them
CN119662571B (zh) * 2024-10-23 2025-10-17 中国电子系统工程第二建设有限公司 一种维生素d3的c1,25位双羟化酶突变体及其基因工程菌与应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6780613B1 (en) * 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
US5331573A (en) * 1990-12-14 1994-07-19 Balaji Vitukudi N Method of design of compounds that mimic conformational features of selected peptides
US5340735A (en) * 1991-05-29 1994-08-23 Cognis, Inc. Bacillus lentus alkaline protease variants with increased stability
US5642292A (en) * 1992-03-27 1997-06-24 Akiko Itai Methods for searching stable docking models of biopolymer-ligand molecule complex
US5786191A (en) * 1992-04-09 1998-07-28 Goldstein; Joyce A. Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450 2C subfamily
US5912120A (en) * 1992-04-09 1999-06-15 The United States Of America As Represented By The Department Of Health And Human Services, Cloning, expression and diagnosis of human cytochrome P450 2C19: the principal determinant of s-mephenytoin metabolism
US5886157A (en) * 1994-02-10 1999-03-23 Vanderbilt University Expression and purification of human cytochrome P450
US6080568A (en) * 1997-08-19 2000-06-27 Genencor International, Inc. Mutant α-amylase comprising modification at residues corresponding to A210, H405 and/or T412 in Bacillus licheniformis
US6432639B1 (en) * 1997-09-10 2002-08-13 Dna Sciences Laboratories, Inc. Isolated CYP3A4 nucleic acid molecules and detection methods
US6162613A (en) * 1998-02-18 2000-12-19 Vertex Pharmaceuticals, Inc. Methods for designing inhibitors of serine/threonine-kinases and tyrosine kinases
US6312917B1 (en) * 1998-12-04 2001-11-06 The University Of North Carolina At Chapel Hill Method of screening candidate compounds for susceptibility to oxidative metabolism
EP2000532A1 (de) * 1999-08-05 2008-12-10 Merck & Co., Inc. Methoden zur Messung von menschlichen Cytochrom P450 (CYP2C8/9)
AUPQ215699A0 (en) * 1999-08-11 1999-09-02 University of Queensland and Vanderbilt University, The Pigment production
US20050032119A1 (en) * 2001-04-02 2005-02-10 Astex Technology Ltd. Crystal structure of cytochrome P450
US20070179716A1 (en) * 2001-04-02 2007-08-02 Astex Therapeutics Limited Crystal structure of cytochrome P450 3A4 and uses thereof
US20060234365A1 (en) * 2001-04-02 2006-10-19 Alison Ward Methods of purification of cytochrome P450 proteins
US7148046B2 (en) * 2001-04-02 2006-12-12 Astex Therapeutics Limited Crystal structure of cytochrome P450
US20050159901A1 (en) * 2001-04-02 2005-07-21 Astex Technology Limited Crystal structure of cytochrome P450
US20040053383A1 (en) * 2001-10-25 2004-03-18 Astex Technology Ltd. Crystals of cytochrome P450 2C9, structures thereof and their use
US20060116826A1 (en) * 2001-10-25 2006-06-01 Astex Therapeutics Limited Crystals of cytochrome P450 2C9, structures thereof and their use
US20040137518A1 (en) * 2002-01-31 2004-07-15 Lambert Millard Hurst CRYSTALLIZED PPARa LIGAND BINDING DOMAIN POLYPEPTIDE AND SCREENING METHODS EMPLOYING SAME
DE02735610T1 (de) * 2002-05-30 2005-06-23 Astex Technology Ltd., Cambridge Methoden zur reinigung von cytochrom p450 proteinen und deren kristallisierung

Also Published As

Publication number Publication date
EP1438337A2 (de) 2004-07-21
WO2003035693A3 (en) 2003-10-30
US20030170842A1 (en) 2003-09-11
DE60214869T2 (de) 2007-04-12
WO2003035693A2 (en) 2003-05-01
DE60214869D1 (de) 2006-11-02
EP1438337B1 (de) 2006-09-20
DE02770119T1 (de) 2005-05-04
JP2005522989A (ja) 2005-08-04

Similar Documents

Publication Publication Date Title
ATE340190T1 (de) Cytochrome p450 2c9 kristalle, strukturen und dessen verwendung
BR0307833A (pt) Sìntese controlada de ziprasidona e suas composições
PT1969007E (pt) Composições e métodos para a produção de uma composição
BRPI0612141A2 (pt) derivados de quinuclidina substituìdos com biciclo-heterociclos fundidos
ATE396731T1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
EA200601555A1 (ru) Замещенные индазол-о-глюкозиды
ATE357434T1 (de) Disubstituierte thiazolylcarboxanilide und ihre verwendung als mikrobizide
DE602004017736D1 (de) Verwendung von rapamycin und dessen derivaten zur behandlung von knochenverlust
TW200518746A (en) Novel inhibitors of hepatitis C virus NS3/NS4A serine protease
DK1631312T3 (da) Sammensætning og fremstillingsmåde til behandling af inflammatorisk tarmsygdom
BRPI0508390A (pt) métodos para tratamento de dor de cáncer de osso através da administração de um antagonista de fator de crescimento de nervo
ATE524741T1 (de) Zusammensetzungen und verwendungen zur stabilisierung von transthyretin und zur hemmung von transthyretin-fehlfaltung
SG170763A1 (en) Ras mutation and compositions and methods related thereto
ATE353880T1 (de) Neue verwendung von pyrimidin- oder triazin-2- carbonsäurenitrilen zur behandlung von krankheiten, die mit cysteinproteaseaktivität assoziiert sind, und neue pyridimidin-2- carbonsäurenitrilderivate
PT1689232E (pt) Método para a protecção de materiais
NO20082195L (no) Abrasivt partikkelmateriale, og fremgangsmate for a gjore er arbeidsstykke plant ved anvendelse derav
DE602005024274D1 (de) Als aurora-kinase-inhibitoren nutzbare thienopyrimidine
DE60014670D1 (de) Antipicornavirale verbindungen und zusammensetzungen, ihre pharmazeutische verwendung, und materialien für ihre synthese
SE0203825D0 (sv) Novel fused heterocycles and uses thereof
MXPA05007771A (es) Procedimientos de tratamiento del dolor articular o para mejorar el sueno usando un agonista/antagonista de estrogeno.
DE502005008416D1 (de) Verwendung von substituierten 2-thio-3,5-dicyano-4-phenyl-6-aminopyridinen bei der behandlung von übelkeit und erbrechen
NO20060093L (no) Plate glykoprotein IB alfa-variant fusjonspolypeptider og fremgangsmater for anvendelse derav
SV2001000379A (es) Compuestos y composiciones antipicornavirales, sus usos farmaceuticos y materiales para su sintesis.
CO5690637A2 (es) Tiazol-(bi) cicloalquil-carboxanilidas
WO2004096857A3 (en) Crystals of cytochrome p450 2c9, structures thereof and their use

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties